Respirology : official journal of the Asian Pacific Society of Respirology
-
Randomized Controlled Trial Multicenter Study
Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study.
This study, in a predominantly Chinese population, investigated the efficacy and safety of a once-daily (o.d.) inhaled ultra-long-acting β2 -agonist indacaterol for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). ⋯ Indacaterol delivered effective bronchodilation with significant improvements in breathlessness and health status in this predominantly Chinese population.